A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash. 6. Juni 2014 Goehler, T., Woerns, M.A., Hebart, H.F., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A.H., Wierecky, J., Galle, P.R., Dhensaw, C., Moehler, M.H., Schimanski, C.C., 2014. J Clin Oncol 32 (suppl; abstr e20724). doi: 10.1200/jco.2014.32.15_suppl.e20724 Abstract Effectiveness of 1st-line treatment options in mRCC – a German RCC-Registry evaluation. Goebell, P.J., Müller, L., Lück, A., Overkamp, F., Vogt, M., Marschner, N., 2014. J Clin Oncol, ASCO GU, San Francisco 32, (suppl.4; abstr 429). doi:10.1200/jco.2014.32.4_suppl.429… Weiterlesen Efficacy of anti-HER2 ReTherapy with Herceptin® at first relapse and/or first occurrence of metastases of HER2-positive breast cancer in clinical routine – 4th interim analysis of the non-interventional study (NIS) ML21589. Hanker, L., Hitschold, T., Grafe, A., Förster, F., Schröder, J., Janssen, J., Reichert, D., Wohlfarth, T., Greinemann, J., Hesse, T., 2014. Ann Oncol 25(suppl4), iv131… Weiterlesen